We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01345006
Recruitment Status : Completed
First Posted : April 29, 2011
Last Update Posted : July 7, 2021
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine )

Brief Summary:
This is a safety and tolerability trial to evaluate the effect of subretinal injection of human embryonic stem cell derived retinal pigment epithelium cells in patients with Stargardt's Macular Dystrophy (SMD).

Condition or disease Intervention/treatment Phase
Stargardt's Macular Dystrophy Biological: MA09-hRPE Phase 1 Phase 2

Detailed Description:

This study is a Phase I/II, open-label, non randomized, sequential, multi-center clinical trial. There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better vision cohort will contain 4 patients. The enrolled cohorts will be as follows:

Three SMD patients- 50,000 MA09-hRPE cells transplanted

Three SMD patients- 100,000 MA09-hRPE cells transplanted

Four Better Vison SMD patients- 100,000 MA09-hRPE cells transplanted

Three SMD patients- 150,000 MA09-hRPE cells transplanted

Three SMD patients- 200,000 MA09-hRPE cells transplanted

Patients will be enrolled sequentially, and within each cohort of 3 patients, each patient's clinical course over the first 6 weeks following cell transplantation will be reviewed by an independent (DSMB) before enrollment is opened for the next 2 patients. A full safety assessment of all 3 patients in each cohort will be made by the DSMB when the 3rd patient in each cohort completes 4 weeks of follow-up, and before the first patient in the next cohort receives a cell transplant. The exception is the better vision group where all patients may be enrolled once DSMB approval has been received.

Each cohort will be enrolled sequentially in turn, with the exception of the better vision cohort which may be enrolled in parallel with the other cohorts.

The day of the cell implantation will be Day 0, and patients will remain in the study until the last visit at 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
Actual Study Start Date : June 16, 2011
Actual Primary Completion Date : August 10, 2015
Actual Study Completion Date : August 10, 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MA09-hRPE
Patients will undergo subretinal injection of MA09-hRPE
Biological: MA09-hRPE

Cohort 1 50,000 cells

Cohort 2 100,000 cells

Cohort 2a Better Vision 100,000 cells

Cohort 3 150,000 cells

Cohort 4 200,000 cells

Primary Outcome Measures :
  1. The safety and tolerance of transplantation of hESC-derived RPE cells MA09-hRPE [ Time Frame: 12 months ]

    The transplantation of hESC-derived RPE cells MA09-hRPE will be considered safe and tolerated in the absence of:

    • Any grade 2 (NCI grading system) or greater adverse event related to the cell product
    • Any evidence that the cells are contaminated with an infectious agent
    • Any evidence that the cells show tumorigenic potential

  2. Safety Assessments [ Time Frame: 12 months ]
    • Adverse Event and Serious Adverse Event assessment
    • Clinical monitoring
    • Serial vital signs
    • Clinical laboratory tests
    • Directed ophthalmological monitoring
    • Monitoring of RPE cells acceptance/integrity/rejection
    • Monitoring of local and systemic infection
    • Monitoring of tumorigenic cell transformation

Secondary Outcome Measures :
  1. Evidence of successful engraftment [ Time Frame: 12 months ]

    Evidence of successful engraftment will consist of:

    • Structural evidence (OCT imaging, fluorescein angiography, autofluorescence photography, slit-lamp examination with fundus photography) that cells have been implanted in the correct location
    • Electroretinographic evidence (mfERG) showing enhanced activity in the implant location

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male or female over 18 years of age.
  • Clinical diagnosis of advanced SMD.
  • If known, the patient's genotype will be recorded in the medical history, if unknown, patient will allow for the submission of a sample for genotyping.Clinical findings consistent with SMD.
  • The visual acuity of the eye to receive the transplant will be no better than 20/400. The visual acuity of the eye in the better vision cohort to receive the transplant will be no better than 20/100.
  • The visual acuity of the eye that is not to receive the transplant will be no better than 20/400 for the worse vision patients and no worse than 20/100 for the better vision patients.
  • Peripheral visual field constriction documented on standard kinetic visual field testing.
  • Electrophysiological findings consistent with SMD.
  • Medically suitable to undergo vitrectomy and subretinal injection.
  • Medically suitable for general anesthesia or waking sedation, if needed.
  • Medically suitable for transplantation of an embryonic stem cell line:
  • Normal serum chemistry (sequential multi-channel analyzer 20 [SMA- 20]) and hematology (complete blood count [CBC], prothrombin time [PT], and activated partial thromboplastin time [aPTT]) screening tests.
  • Negative urine screen for drugs of abuse.
  • Negative human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) serologies.
  • No history of malignancy,with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.
  • Negative cancer screening within previous 6 months:
  • complete history & physical examination;
  • dermatological screening exam for malignant lesions;
  • negative fecal occult blood test & if over age 50 years, negative colonoscopy within previous 7 years;
  • negative chest roentgenogram (CXR);
  • normal CBC & manual differential;
  • negative urinalysis (U/A);
  • normal thyroid exam;
  • if male, normal testicular examination; if over age 40, digital rectal examination (DRE) and prostate specific antigen (PSA);
  • if female, normal pelvic examination with Papanicolaou smear; and
  • if female, normal clinical breast exam and if 40 years of age or older, negative mammogram.
  • If female and of childbearing potential, willing to use two effective forms of birth control during the study.
  • If male, willing to use barrier and spermicide contraception during the study.
  • Willing to defer all future blood, blood component or tissue donation. -Able to understand and willing to sign the informed consent.

Exclusion Criteria:

  • History of malignancy,with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.
  • History of myocardial infarction in previous 12 months.
  • History of diabetes mellitus.
  • Any immunodeficiency.
  • Any current immunosuppressive therapy other than intermittent or low dose corticosteroids.
  • Serologic evidence of infection with Hepatitis B, Hepatitis C, or HIV.
  • Current participation in any other clinical trial.
  • Participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration.
  • Any other sight-threatening ocular disease.
  • Any chronic ocular medications.
  • Any history of retinal vascular disease (compromised blood-retinal barrier.
  • Glaucoma.
  • Uveitis or other intraocular inflammatory disease.
  • Significant lens opacities or other media opacity.
  • Ocular lens removal within previous 3 months.
  • If female, pregnancy or lactation.
  • Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01345006

Layout table for location information
United States, California
Jules Stein Eye Institute, UCLA School of Medicine
Los Angeles, California, United States, 90095
United States, Florida
Bascom Palmer Eye institute
Miami, Florida, United States, 33136
United States, Pennsylvania
Wills Eye Institute-Mid Atlantic Retina
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Astellas Institute for Regenerative Medicine
Layout table for investigator information
Study Director: Medical Director Astellas Institute for Regenerative Medicine
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Astellas Institute for Regenerative Medicine
ClinicalTrials.gov Identifier: NCT01345006    
Other Study ID Numbers: 7316-CL-0001
ACT SMD 01 MA09-hRPE ( Other Identifier: Sponsor )
ACT MA09-hRPE SMD-001 ( Other Identifier: Sponsor )
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: July 7, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."
Keywords provided by Astellas Pharma Inc ( Astellas Institute for Regenerative Medicine ):
juvenile macular dystrophy
fundus flavimaculatus
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Stargardt Disease
Retinal Degeneration
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn